Our Approach

Scientific Approach is Driving Efficacy AND Safety

MetroBiotech’s platform focuses on restoring and sustaining NAD+ levels, a critical cofactor for mitochondrial function, gene regulation, and cellular resilience. Our early human trials demonstrated up to a 200% increase in NAD+ levels within 14 days, without any drug-related serious adverse events (SAEs).

*without any drug-related adverse events (SAEs)

Unlike over-the-counter supplements — often manufactured with inconsistent quality and impurity profiles — our compounds are produced under FDA oversight, adhering to pharmaceutical-grade manufacturing standards to ensure purity, safety, and bioavailability.

Poised for Significant Growth Across Multiple Use Cases

MetroBiotech’s near-term priorities include:

01

Advancing MIB-626 and MIB-725 through early clinical development for AKI.

02

Reporting top-line results from ongoing muscle strength and Alzheimer’s disease trials by year-end 2025, and advancing into a multi-center phase 2b trial in 2026

03

Completing the ongoing chronic kidney disease trials after leveraging insights from NAD+ biology.

04

Continuing research on NAD+ metabolism — measuring synthesis and destruction rates in vivo to identify biomarkers and optimize interventions.

05

Pursuing strategic partnerships to broaden clinical development and future commercialization.

06

Targeting both acute and chronic use cases through robust drug registration strategies.